Lisanne C Verbruggen, Judith L Kok, Leontien C M Kremer, Geert O Janssens, Paul J Nederkoorn, Adriaan Penson, A Birgitta Versluijs, Andrica C H de Vries, Ardine M J Reedijk, Dorine Bresters, Eelco W Hoving, Eline van Dulmen-den Broeder, Jacqueline J Loonen, Judith de Bont, Joyce Wilbers, Marloes Louwerens, Margriet van der Heiden-van der Loo, Marry M van den Heuvel-Eibrink, Saskia M F Pluijm, Sebastian J C M M Neggers, Wim J E Tissing, Yvo B W E M Roos, Cécile M Ronckers, Jop C Teepen, Helena J H van der Pal
{"title":"DCCSS-LATER队列中儿童癌症幸存者接受上半身放疗后发生脑血管事件的长期风险和特征。","authors":"Lisanne C Verbruggen, Judith L Kok, Leontien C M Kremer, Geert O Janssens, Paul J Nederkoorn, Adriaan Penson, A Birgitta Versluijs, Andrica C H de Vries, Ardine M J Reedijk, Dorine Bresters, Eelco W Hoving, Eline van Dulmen-den Broeder, Jacqueline J Loonen, Judith de Bont, Joyce Wilbers, Marloes Louwerens, Margriet van der Heiden-van der Loo, Marry M van den Heuvel-Eibrink, Saskia M F Pluijm, Sebastian J C M M Neggers, Wim J E Tissing, Yvo B W E M Roos, Cécile M Ronckers, Jop C Teepen, Helena J H van der Pal","doi":"10.1002/ijc.35275","DOIUrl":null,"url":null,"abstract":"<p><p>Cerebrovascular events (CVEs) are serious late adverse events among childhood cancer survivors. We estimated the incidence and risk factors of symptomatic CVEs and described the clinical characteristics among childhood cancer survivors after upper body radiotherapy. The Dutch Childhood Cancer Survivor Study LATER cohort study includes 5-year childhood cancer survivors diagnosed <age 18 years in the period 1963-2001. Data about CVEs were retrieved from medical records of survivors treated with upper body radiotherapy (n = 1633). Multivariable Cox and logistic regression models were used to identify potential risk factors for developing a symptomatic CVE. In 107 survivors with upper body radiotherapy, a CVE emerged, at a median age of 35.5 years. Cumulative incidence 40 years after diagnosis was 9.1% (95% CI: 7.2%-11.6%). A cranial radiotherapy prescription dose >50 Gy was associated with 6-fold increased risk, compared to upper body radiotherapy not involving the cranium (hazard ratio = 6.3, 95%CI: 3.3-12.1). In a subgroup with available data on lifestyle and comorbidities, hypertension (odds ratio[OR] = 6.2, 95%CI: 1.6-23.8) and obesity (BMI≥30 vs. <30 = 2.95, 95%CI: 1.1-8.0) significantly increased CVE risk. During CVE episode, 17 (16%) had a life-threatening situation, and two (2%) others died. In 28%, a second CVE developed during follow-up. At end of follow-up, 29% were deceased, and 40% of those alive were unable to carry out normal activities/active work. Childhood cancer survivors treated with higher doses of cranial radiotherapy are at highest risk for developing CVEs. CVEs occur at a young age and cause a high morbidity. Studies to investigate risk-reducing secondary preventive interventions are warranted.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term risk and characteristics of cerebrovascular events after upper body radiotherapy among childhood cancer survivors in the DCCSS-LATER cohort.\",\"authors\":\"Lisanne C Verbruggen, Judith L Kok, Leontien C M Kremer, Geert O Janssens, Paul J Nederkoorn, Adriaan Penson, A Birgitta Versluijs, Andrica C H de Vries, Ardine M J Reedijk, Dorine Bresters, Eelco W Hoving, Eline van Dulmen-den Broeder, Jacqueline J Loonen, Judith de Bont, Joyce Wilbers, Marloes Louwerens, Margriet van der Heiden-van der Loo, Marry M van den Heuvel-Eibrink, Saskia M F Pluijm, Sebastian J C M M Neggers, Wim J E Tissing, Yvo B W E M Roos, Cécile M Ronckers, Jop C Teepen, Helena J H van der Pal\",\"doi\":\"10.1002/ijc.35275\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cerebrovascular events (CVEs) are serious late adverse events among childhood cancer survivors. We estimated the incidence and risk factors of symptomatic CVEs and described the clinical characteristics among childhood cancer survivors after upper body radiotherapy. The Dutch Childhood Cancer Survivor Study LATER cohort study includes 5-year childhood cancer survivors diagnosed <age 18 years in the period 1963-2001. Data about CVEs were retrieved from medical records of survivors treated with upper body radiotherapy (n = 1633). Multivariable Cox and logistic regression models were used to identify potential risk factors for developing a symptomatic CVE. In 107 survivors with upper body radiotherapy, a CVE emerged, at a median age of 35.5 years. Cumulative incidence 40 years after diagnosis was 9.1% (95% CI: 7.2%-11.6%). A cranial radiotherapy prescription dose >50 Gy was associated with 6-fold increased risk, compared to upper body radiotherapy not involving the cranium (hazard ratio = 6.3, 95%CI: 3.3-12.1). In a subgroup with available data on lifestyle and comorbidities, hypertension (odds ratio[OR] = 6.2, 95%CI: 1.6-23.8) and obesity (BMI≥30 vs. <30 = 2.95, 95%CI: 1.1-8.0) significantly increased CVE risk. During CVE episode, 17 (16%) had a life-threatening situation, and two (2%) others died. In 28%, a second CVE developed during follow-up. At end of follow-up, 29% were deceased, and 40% of those alive were unable to carry out normal activities/active work. Childhood cancer survivors treated with higher doses of cranial radiotherapy are at highest risk for developing CVEs. CVEs occur at a young age and cause a high morbidity. Studies to investigate risk-reducing secondary preventive interventions are warranted.</p>\",\"PeriodicalId\":180,\"journal\":{\"name\":\"International Journal of Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ijc.35275\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ijc.35275","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Long-term risk and characteristics of cerebrovascular events after upper body radiotherapy among childhood cancer survivors in the DCCSS-LATER cohort.
Cerebrovascular events (CVEs) are serious late adverse events among childhood cancer survivors. We estimated the incidence and risk factors of symptomatic CVEs and described the clinical characteristics among childhood cancer survivors after upper body radiotherapy. The Dutch Childhood Cancer Survivor Study LATER cohort study includes 5-year childhood cancer survivors diagnosed 50 Gy was associated with 6-fold increased risk, compared to upper body radiotherapy not involving the cranium (hazard ratio = 6.3, 95%CI: 3.3-12.1). In a subgroup with available data on lifestyle and comorbidities, hypertension (odds ratio[OR] = 6.2, 95%CI: 1.6-23.8) and obesity (BMI≥30 vs. <30 = 2.95, 95%CI: 1.1-8.0) significantly increased CVE risk. During CVE episode, 17 (16%) had a life-threatening situation, and two (2%) others died. In 28%, a second CVE developed during follow-up. At end of follow-up, 29% were deceased, and 40% of those alive were unable to carry out normal activities/active work. Childhood cancer survivors treated with higher doses of cranial radiotherapy are at highest risk for developing CVEs. CVEs occur at a young age and cause a high morbidity. Studies to investigate risk-reducing secondary preventive interventions are warranted.
期刊介绍:
The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories:
-Cancer Epidemiology-
Cancer Genetics and Epigenetics-
Infectious Causes of Cancer-
Innovative Tools and Methods-
Molecular Cancer Biology-
Tumor Immunology and Microenvironment-
Tumor Markers and Signatures-
Cancer Therapy and Prevention